These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 15793299)

  • 1. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
    Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
    Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
    Jacquemart IC; Springs AE; Chen WY
    Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression.
    Baturin DA; Alimova IN; Anisimov VN; Popovich IG; Zabezhinski MA; Provinciali M; Mancini R; Franceschi C
    Neuro Endocrinol Lett; 2001 Dec; 22(6):441-7. PubMed ID: 11781542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
    Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
    Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
    Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
    Rovero S; Boggio K; Di Carlo E; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G
    Gene Ther; 2001 Mar; 8(6):447-52. PubMed ID: 11313823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.